Memantine (monotherapy) - Dementia
You are here : Home > Formulary Search > Memantine (monotherapy) - Dementia
Status 1
- Not Specified
This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.
Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).
Documentation
PAD Profile
Other Indications
Below are listed other indications that Memantine (monotherapy) is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Dementia.
Committee Recommendations (2)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the updated resource pack for use by primary care prescribers for managing non-cognitive symptoms in people living with dementia.
Acetylcholinesterase inhibitors are 1st-line treatment option for mild to moderate Alzheimer's disease. Memantine is licensed for the treatment of patients with moderate to severe Alzheimer's disease and is also a treatment option for dementia with Lewy bodies, vascular dementia and Parkinson's dementia.
See below for the local treatment pathways.
The local pathways advise that memantine MONOTHERAPY should be initiated or recommended by a specialist and:
- should be offered to patients with severe Alzheimer's disease
- may be used in moderate disease where an AChE inhibitor is not tolerated or contraindicated
- may be used in dementia with Lewy bodies if AChE inhibitors are not tolerated or contraindicated (unlicensed)
- may be used in Vascular dementia ONLY if co-morbid Alzheimer’s disease, or dementia with Lewy Bodies (unlicensed)
Memantine MONOTHERAPY has been recommended as BLUE (with information sheet) for those patients who are stable and suitable for discharge from specialist care.
AMBER shared care will apply for the patients that are not suitable for discharge and who will continue to receive follow up by SABPT
COMBINATION THERAPY - Memantine is appropriate for Primary Care initiation (GREEN status) when being added to existing AChE inhibitor therapy (i.e. combination therapy) in patients with worsening cognitive function or other markers of deterioration. See separate PAD page for further information https://surreyccg.res-systems.net/pad/Search/DrugConditionProfile/5204
Note - the branded memantine, Ebixa, has been assigned a BLACK traffic light status and should not be prescribed